{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:28Z","timestamp":1792786108844,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"},{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Abstract Objective<\/jats:title>\n                    <jats:p>In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated \u226590% efficacy in preventing herpes zoster (HZ) in all age groups \u226550\u2009years. Given the increased HZ risk associated with certain underlying autoimmune diseases or their treatment regimes, we conducted a post hoc analysis of RZV\u2019s efficacy against HZ and safety profile [specifically, the occurrence of serious adverse events (SAEs)] in ZOE-50\/70 participants who reported pre-existing potential immune-mediated diseases (pIMDs) at enrolment and were not on immunosuppressive therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults aged \u226550 (ZOE-50) and \u226570 (ZOE-70) years were randomized to receive two doses of RZV or placebo 2\u2009months apart. In this subgroup analysis of participants with at least one pIMD at enrolment, the efficacy was calculated for two-dose recipients who did not develop confirmed HZ before 30\u2009days post-dose 2. SAE occurrence was evaluated for all participants who received at least one dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 14\u2009645 RZV and 14\u2009660 placebo recipients from the ZOE-50\/70 studies, 983 and 960, respectively, reported at least one pre-existing pIMD at enrolment and were included in these analyses. The most frequent pre-existing conditions were psoriasis, spondyloarthropathy and RA. Efficacy against HZ was 90.5% (95% CI: 73.5, 97.5%) overall with the lowest being 84.4% (95% CI: 30.8, 98.3%) in the 70\u201379-year-old age group. SAEs and fatal SAEs were similar between RZV and placebo recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In ZOE-50\/70 participants with pre-existing pIMDs, RZV was highly efficacious against HZ and SAE incidence was similar between RZV and placebo recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT01165177 (ZOE-50), NCT01165229 (ZOE-70).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa424","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T15:27:04Z","timestamp":1593790024000},"page":"1226-1233","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled\n                    <i>post hoc<\/i>\n                    analysis on two parallel randomized trials"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-058X","authenticated-orcid":false,"given":"Alemnew F","family":"Dagnew","sequence":"first","affiliation":[{"name":"GSK, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Rausch","sequence":"additional","affiliation":[{"name":"GSK, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Herv\u00e9","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufik","family":"Zahaf","sequence":"additional","affiliation":[{"name":"GSK, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J","family":"Levin","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schuind","sequence":"additional","affiliation":[{"name":"GSK, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ZOE-50\/70 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2021030705483380100_keaa424-B1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"2021030705483380100_keaa424-B2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for herpes zoster: a systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2021030705483380100_keaa424-B3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijid.2015.03.022","article-title":"Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia","volume":"34","author":"Kawai","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2021030705483380100_keaa424-B4","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2021030705483380100_keaa424-B5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2021030705483380100_keaa424-B6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","article-title":"Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain","volume":"167","author":"Mareque","year":"2019","journal-title":"Public Health"},{"key":"2021030705483380100_keaa424-B7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"key":"2021030705483380100_keaa424-B8","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021030705483380100_keaa424-B9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2021030705483380100_keaa424-B10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaad.2019.03.017","article-title":"A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation","volume":"81","author":"Baumrin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2021030705483380100_keaa424-B11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1177\/0961203318792352","article-title":"Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort","volume":"27","author":"Yang","year":"2018","journal-title":"Lupus"},{"key":"2021030705483380100_keaa424-B12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Herpes zoster in tofacitinib: risk is further increased with glucocorticoids but not methotrexate","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021030705483380100_keaa424-B13","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2021030705483380100_keaa424-B14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40264-016-0430-0","article-title":"Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster","volume":"39","author":"Yamaoka","year":"2016","journal-title":"Drug Saf"},{"key":"2021030705483380100_keaa424-B15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11926-019-0832-y","article-title":"In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis","volume":"21","author":"Siegel","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2021030705483380100_keaa424-B16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2021030705483380100_keaa424-B17","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/rheumatology\/kez175","article-title":"Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis","volume":"58","author":"Almanzar","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705483380100_keaa424-B18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705483380100_keaa424-B19","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"2021030705483380100_keaa424-B20","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials","volume":"37","author":"Lopez-Fauqued","year":"2019","journal-title":"Vaccine"},{"key":"2021030705483380100_keaa424-B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/OARRR.S38443","article-title":"Retrospective analysis of the clinical course of patients treated for polymyalgia","volume":"5","author":"Do-Nguyen","year":"2013","journal-title":"Open Access Rheumatol"},{"key":"2021030705483380100_keaa424-B22","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1016\/j.vaccine.2019.09.028","article-title":"Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials","volume":"37","author":"Willer","year":"2019","journal-title":"Vaccine"},{"key":"2021030705483380100_keaa424-B23","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","article-title":"Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials","volume":"15","author":"Oostvogels","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2021030705483380100_keaa424-B24","doi-asserted-by":"crossref","first-page":"e68218","DOI":"10.1371\/journal.pone.0068218","article-title":"Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock","volume":"8","author":"Allantaz-Frager","year":"2013","journal-title":"PLoS One"},{"key":"2021030705483380100_keaa424-B25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"2021030705483380100_keaa424-B26","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021030705483380100_keaa424-B27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"2021030705483380100_keaa424-B28","first-page":"181","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1226\/36434046\/keaa424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1226\/36434046\/keaa424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:50:19Z","timestamp":1615078219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/3\/1226\/5903548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2021,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa424","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,10]]}}}